Uterine Fibroid Drug Esmya May Be Linked To Liver Damage, EU Regulators Warn
European regulators are raising concerns that the uterine fibroid drug Esmya, awaiting approval in the U.S., may be linked to liver damage and liver failure risks.
European regulators are raising concerns that the uterine fibroid drug Esmya, awaiting approval in the U.S., may be linked to liver damage and liver failure risks.